Home
NBIX
NBIX News

Latest Neurocrine Biosciences Inc. (NBIX) News on June 21, 2025

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

a day ago

Exploring 3 High Growth Tech Stocks In The US Market

Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

PR Newswire

a day ago

Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

Argus Research

11 days ago

NBIX: What does Argus have to say about NBIX?

MT Newswires

12 days ago

Neurocrine Biosciences Names Lewis Choi as Chief Information Officer

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

PR Newswire

12 days ago

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

CPRX or NBIX: Which Is the Better Value Stock Right Now?

Zacks

18 days ago

CPRX or NBIX: Which Is the Better Value Stock Right Now?

MT Newswires

19 days ago

Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

PR Newswire

19 days ago

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

GlobeNewswire

22 days ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched

Insider Monkey

24 days ago

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched

MT Newswires

24 days ago

Neurocrine Reports Positive Data in Mid-Stage Schizophrenia Trial

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

PR Newswire

24 days ago

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In The US Market

MT Newswires

a month ago

Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

PR Newswire

a month ago

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

PR Newswire

a month ago

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

PR Newswire

a month ago

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Zacks

a month ago

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia

PR Newswire

a month ago

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia

Argus Research

a month ago

NBIX: Lowering target price to $123.00

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential

Insider Monkey

a month ago

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential

Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality

Simply Wall St.

a month ago

Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Simply Wall St.

a month ago

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

PR Newswire

a month ago

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

MT Newswires

a month ago

Neurocrine Biosciences Insider Sold Shares Worth $3,305,952, According to a Recent SEC Filing

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a month ago

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday

Insider Monkey

a month ago

Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday

Argus Research

a month ago

NBIX: Raising target price to $125.00

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug

Investor's Business Daily

2 months ago

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

PR Newswire

2 months ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

MT Newswires

2 months ago

BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating

MT Newswires

2 months ago

UBS Adjusts Price Target on Neurocrine Biosciences to $152 From $137, Buy Rating Kept

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Neurocrine Biosciences Inc Earnings Call

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

PR Newswire

2 months ago

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

MT Newswires

2 months ago

RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating

GuruFocus.com

2 months ago

Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ...

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks

2 months ago

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

Zacks

2 months ago

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

MT Newswires

2 months ago

Neurocrine Biosciences Q1 Non-GAAP Earnings Fall, Sales Rise; Maintains 2025 Guidance

Associated Press Finance

2 months ago

Neurocrine: Q1 Earnings Snapshot

Neurocrine begins Phase III programme for schizophrenia treatment

Clinical Trials Arena

2 months ago

Neurocrine begins Phase III programme for schizophrenia treatment

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential

Insider Monkey

2 months ago

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential

MT Newswires

2 months ago

Neurocrine Biosciences Starting Phase 3 Trial of Prospective Schizophrenia Medication

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

PR Newswire

2 months ago

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

2 months ago

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?

Zacks

2 months ago

Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?

PR Newswire

2 months ago

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Argus Research

2 months ago

NBIX: Raising target price to $107.00

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case

Simply Wall St.

2 months ago

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case

Argus Research

2 months ago

NBIX: Raising target price to $101.00

MT Newswires

2 months ago

Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

PR Newswire

2 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

MT Newswires

2 months ago

Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says

MT Newswires

2 months ago

RBC Upgrades Neurocrine Biosciences to Outperform From Sector Perform, Trims Price Target to $137 From $138

Argus Research

2 months ago

NBIX: Lowering target price to $92.00

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Zacks

2 months ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

MT Newswires

3 months ago

Neurocrine Biosciences Appoints New Chief Medical Officer

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

PR Newswire

3 months ago

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

MT Newswires

3 months ago

UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating

MT Newswires

3 months ago

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating

MT Newswires

3 months ago

RBC Trims Price Target on Neurocrine Biosciences to $138 From $139, Keeps Sector Perform Rating

Argus Research

3 months ago

NBIX: Lowering target price to $112.00

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

PR Newswire

3 months ago

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Argus Research

3 months ago

NBIX: Raising target price to $122.00

Exploring High Growth Tech Stocks in US for March 2025

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks in US for March 2025

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza

Clinical Trials Arena

3 months ago

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

PR Newswire

3 months ago

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey

3 months ago

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

PR Newswire

3 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

The Wall Street Journal

3 months ago

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

PR Newswire

3 months ago

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

MT Newswires

3 months ago

RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions

Simply Wall St.

4 months ago

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults

Clinical Trials Arena

4 months ago

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

PR Newswire

4 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Argus Research

4 months ago

NBIX: Lowering target price to $119.00

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

PR Newswire

4 months ago

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Argus Research

4 months ago

NBIX: Raising target price to $122.00

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

PR Newswire

4 months ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

High Growth Tech Stocks To Watch In February 2025

Simply Wall St.

4 months ago

High Growth Tech Stocks To Watch In February 2025

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?

Insider Monkey

4 months ago

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

4 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

MT Newswires

4 months ago

Sector Update: Health Care Stocks Mixed Premarket Friday

MT Newswires

4 months ago

Neurocrine Biosciences Approves $500 Million Share Repurchase Program

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

PR Newswire

4 months ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Argus Research

4 months ago

NBIX: Lowering target price to $120.00

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

Insider Monkey

4 months ago

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

MT Newswires

4 months ago

Neurocrine Biosciences Insider Sold Shares Worth $1,613,923, According to a Recent SEC Filing

MT Newswires

4 months ago

Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Hold Rating, $138 Price Target

Why Neurocrine Biosciences Stock Sank Today

Motley Fool

4 months ago

Why Neurocrine Biosciences Stock Sank Today

MT Newswires

4 months ago

UBS Adjusts Neurocrine Biosciences Price Target to $154 From $176, Maintains Buy Rating

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week

Insider Monkey

4 months ago

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

Insider Monkey

4 months ago

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years

Simply Wall St.

4 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

Investor's Business Daily

4 months ago

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Barrons.com

4 months ago

These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Benzinga

4 months ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

MT Newswires

4 months ago

RBC Capital Adjusts Price Target on Neurocrine Biosciences to $148 From $154, Keeps Sector Perform Rating

MT Newswires

4 months ago

Wedbush Adjusts Price Target on Neurocrine Biosciences to $147 From $157, Keeps Outperform Rating

Share on Social Networks: